Side-by-side comparison of AI visibility scores, market position, and capabilities
Nusano is a Seattle-based startup developing a proprietary linear accelerator platform to produce uranium-free diagnostic and therapeutic radioisotopes for the radiopharmaceutical industry; raised $22M in 2022;
Nusano is a radioisotope production technology company founded in 2017 and headquartered in Seattle, Washington. The company has developed a proprietary high-current linear accelerator (linac) technology designed to produce diagnostic and therapeutic radioisotopes outside of the nuclear reactor supply chain. Conventional medical radioisotope production relies heavily on aging nuclear research reactors and uranium-based processes — creating chronic supply chain vulnerabilities that periodically cause shortages of critical isotopes like Tc-99m (used in millions of cardiac and oncology scans annually). Nusano's linac technology produces isotopes without uranium, offering pharmaceutical manufacturers and hospitals a more stable, reactor-independent supply alternative.
Saluda Medical is the pioneer of closed-loop spinal cord stimulation (SCS); FDA-approved Evoke SCS system with real-time neural feedback; raised $100M in Jan 2025; received FDA clearance for automated EVA programming platform.
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US operations in Marlborough, Massachusetts), Saluda''s flagship product is the Evoke Spinal Cord Stimulation (SCS) System — the world''s first SCS system that senses and measures neural responses to stimulation (evoked compound action potentials, or ECAPs) and automatically adjusts therapy in real time based on each patient''s neurophysiological feedback. This closed-loop approach provides more precise, consistent pain relief compared to conventional open-loop SCS systems.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.